Segarra A
Servicio de Nefrología, Hospital Vall d'Hebron, Barcelona.
Nefrologia. 2010;30(5):501-7. doi: 10.3265/Nefrologia.pre2010.Jul.10526.
Progress in understanding the pathogenesis of IgA nephropathy has shown that probably there is no a single IgA nephropathy with the same pathogenic mechanism, clinical course and response to therapy. The evidence currently available suggests the existence of at least two possible mechanisms of IgA deposition in the renal mesangium. In a small percentage of patients, mesangial deposition of IgA1 colocalizes with secretory component, indicating that the deposited IgA1 in glomeruli originates completely or partly in the mucose-associated lymphoid tissue. This deposition pattern has been associated with activation of complement by the lectin pathway and has been associated with a worse prognosis, although this last statement needs to be confirmed in long-term studies. The mechanisms responsible for secretory IgA deposition are not known. In the majority of patients with IgA nephropathy secretory component is not detectable in the mesangium. In these cases, the presence of elevated circulating levels of galactose-deficient IgA, produced by bone marrow plasma cells would be a predisposing factor but not sufficient to induce nephropathy. To produce kidney disease, galactose-deficient IgA1 must be deposited in the renal mesangium, and once there, either by interaction with specific receptors (CD71?), by direct activation of complement or by being the target of an IgG autoimmune response anti-IgA, induce activation, proliferation and increased mesangial matrix synthesis and eventually cell injury. In parallel, galactose-deficient IgA, through interaction with the RR Fc alpha/gamma, may activate circulating lymphocytes and monocytes and enhance their response to chemoattractants produced by the mesangial cell, causing, thus, the inflammatory infiltrate to initiate and maintain the interstitial injury. In the next few years, advances recently added to the knowledge of the pathogenesis of nephropathy IgA1 could provide new variables that allow walking in the direction of having a classification of patients based not only in clinical and morphological criteria but also having a greater pathogenic basis.
对IgA肾病发病机制的理解进展表明,可能不存在具有相同致病机制、临床病程和治疗反应的单一IgA肾病。目前可得的证据提示,至少存在两种IgA在肾系膜沉积的可能机制。在一小部分患者中,IgA1在系膜的沉积与分泌成分共定位,这表明肾小球中沉积的IgA1完全或部分源自黏膜相关淋巴组织。这种沉积模式与凝集素途径激活补体有关,并且与较差的预后相关,尽管这一结论有待长期研究证实。导致分泌型IgA沉积的机制尚不清楚。在大多数IgA肾病患者中,系膜中检测不到分泌成分。在这些病例中,骨髓浆细胞产生的循环中半乳糖缺陷型IgA水平升高可能是一个易感因素,但不足以诱发肾病。要引发肾脏疾病,半乳糖缺陷型IgA1必须沉积在肾系膜中,一旦沉积在此,它可能通过与特定受体(CD71?)相互作用、直接激活补体或成为抗IgA的IgG自身免疫反应的靶标,诱导激活、增殖并增加系膜基质合成,最终导致细胞损伤。同时,半乳糖缺陷型IgA通过与RR Fcα/γ相互作用,可能激活循环中的淋巴细胞和单核细胞,并增强它们对系膜细胞产生的趋化因子的反应,从而引发炎症浸润并维持间质损伤。在未来几年里,IgA1肾病发病机制知识的最新进展可能会提供新的变量,使我们不仅能够基于临床和形态学标准,而且能够基于更强的致病基础对患者进行分类。